February's Biggest Biotech Loser Bounces Back
In the following video, Motley Fool health-care analyst David Williamson takes a look at the dizzying ups and downs of Peregrine Pharmaceuticals . The ongoing saga with the company's leading candidate cancer drug bavituximab has seen shares soar 80% in January, plummet 39% in February, and rally again this month, leaving the stock up 20% overall for the year. David gives investors his take on the drug and where he thinks this wild ride is finally going to end up.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article February's Biggest Biotech Loser Bounces Back originally appeared on Fool.com.David Williamson has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.